4.5 Article

Value of genetic testing for pediatric epilepsy: Driving earlier diagnosis of ceroid lipofuscinosis type 2 Batten disease

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Genetics & Heredity

Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients

Sara E. Mole et al.

Summary: These guidelines provide robust evidence-based, expert-agreed recommendations on the risks/benefits of disease-modifying treatments and the medical interventions used to manage CLN2 disease. The program addresses the clinical need to complement other available information.

ORPHANET JOURNAL OF RARE DISEASES (2021)

Review Health Care Sciences & Services

Changing Times for CLN2 Disease: The Era of Enzyme Replacement Therapy

Nicola Specchio et al.

THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2020)

Review Clinical Neurology

Therapeutic landscape for Batten disease: current treatments and future prospects

Tyler B. Johnson et al.

NATURE REVIEWS NEUROLOGY (2019)

Article Medicine, General & Internal

Study of Intraventricular Cerliponase Alfa for CLN2 Disease

Angela Schulz et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Article Genetics & Heredity

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria

Keith Nykamp et al.

GENETICS IN MEDICINE (2017)

Article Pediatrics

Early-Life Epilepsies and the Emerging Role of Genetic Testing

Anne T. Berg et al.

JAMA PEDIATRICS (2017)

Review Clinical Neurology

Genetics of Epilepsy in Clinical Practice

Samuel F. Berkovic

EPILEPSY CURRENTS (2015)

Article Clinical Neurology

POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders

Russell P. Saneto et al.

SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2010)